Month: March 2024

Wegovy for Medicare Beneficiaries; Bariatric Surgery Restrictions Eased by GLP-1 Costs; $6B Spend on GLP-1s by Medicare in 2022; $5 Per Month to Manufacture Ozempic; Viking Therapeutics Stock Charges

Wegovy for Medicare Beneficiaries; Bariatric Surgery Restrictions Eased by GLP-1 Costs; $6B Spend on GLP-1s by Medicare in 2022; $5 Per Month to Manufacture Ozempic; Viking Therapeutics Stock Charges

March 31, 2024 No Comments

AT A GLANCE San Diego biotech Viking Therapeutics shares were up 20% on news that the oral version of dual GLP-1/GIP drug VK2735 had succeeded its phase 1 trial. Peter Loftus at The Wall Street Journal reports CVS Health, Elevance Health and Kaiser Permanente would cover Wegovy for Medicare beneficiaries. Miriam E. Tucker at Medscape suggests ‘GLP-1 Costs May Ease Restrictions to Bariatric Surgery.’ The Kaiser Family Foundation analyzed Medicare

Read More »
Medicare Coverage for GLP-1 meds; Oprah and Weight Stigma; Vast Underusage of Bariatric Surgery; Digital Diabetes Tools not Worth It; Obesity Costs in Pennsylvania at $20B.

Medicare Coverage for GLP-1 meds; Oprah and Weight Stigma; Vast Underusage of Bariatric Surgery; Digital Diabetes Tools not Worth It; Obesity Costs in Pennsylvania at $20B.

March 24, 2024 No Comments

AT A GLANCE The Wall Street Journal’s Peter Loftus writes ‘…Medicare Opens Door for Covering Obesity Drugs.’ From Dani Blum at The New York Times, media icon Oprah Winfrey takes on weight stigma in her ABC News Special… starting with her own. Respected bariatric surgeon Dr. Bruce Schirmer, writes in JAMA Surgery on Metabolic Bariatric Surgery – A Vastly Underused Treatment. STAT reports digital tools for diabetes management

Read More »
Anti-Obesity Meds for those with HIV; Medicare Approval Likely for Wegovy; Amazon Delivery of GLP-1 Meds; Obesity Treatment in Primary Care

Anti-Obesity Meds for those with HIV; Medicare Approval Likely for Wegovy; Amazon Delivery of GLP-1 Meds; Obesity Treatment in Primary Care

March 17, 2024 No Comments

AT A GLANCE Nature journal reports ‘…People with HIV are the latest group to benefit from the new generation of anti-obesity drugs.’ STAT suggests FDA approval of Wegovy for heart benefits ‘…could provide a backdoor way to expand access to the drug for people on Medicare.’ Peter Loftus at The Wall Street Journal reveals those ‘…seeking a popular new weight-loss drug will have a new home-delivery option from

Read More »
GLP-1 for Kidney Disease; FDA approves Wegovy for Cardiovascular Disease; Eli Lilly’s new Ad Campaign ahead of the Oscars; Obesity is South Africa’s New HIV Epidemic.

GLP-1 for Kidney Disease; FDA approves Wegovy for Cardiovascular Disease; Eli Lilly’s new Ad Campaign ahead of the Oscars; Obesity is South Africa’s New HIV Epidemic.

March 10, 2024 No Comments

AT A GLANCE Novo Nordisk’s FLOW trial of Ozempic demonstrates a ‘…24% reduction in the risk of kidney disease-related events…’ STAT reports on Novo Nordisk’s phase 1 trial of experimental oral medicine amycretin, with an average of 13.1% weight loss after 12 weeks. Reuters informs on Novo Nordisk market cap of $556 billion and had surpassed that of Tesla. The FDA approved ‘…a new indication for use

Read More »
A Billion People Obese Worldwide; An Obesity Vaccine? – from Novo Nordisk and Vivani; Survodutide for Liver Disease; Bariatric Surgery Cures Diabetes

A Billion People Obese Worldwide; An Obesity Vaccine? – from Novo Nordisk and Vivani; Survodutide for Liver Disease; Bariatric Surgery Cures Diabetes

March 3, 2024 No Comments

AT A GLANCE STAT reports on Marcus Schindler, Novo’s chief scientific officer, who wants to ‘…make long-lasting GLP-1 molecules…’ with ‘…vaccine-like properties.’ NPM-115 and NPM-139 are miniature, subdermal GLP-1 implants from NASDAQ-listed company Vivani Medical, Inc. that provide once- or twice-yearly administration. STAT reports from a study in The Lancet that ‘…more than 1 billion people – or one in eight people worldwide –

Read More »
Categories
Archives
Scroll to Top
Skip to content